Received Jul 2, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | CD44A | — |
her pregnancy test was positive; This non-serious prospective pregnancy case was reported by a other health professional via call center representative and described the occurrence of vaccine exposure during pregnancy in a female patient who received Men B NVS (Bexsero) suspension for injection in pre-filled syringe (batch number CD44A with expiry date 31-MAR-2028) for prophylaxis. On 16-JUN-2026, the patient received the 3rd dose of Bexsero. On an unknown date, an unknown time after receiving Bexsero, the patient experienced vaccine exposure during pregnancy (Verbatim: her pregnancy test was positive). The outcome of the vaccine exposure during pregnancy was not applicable. Pregnancy exposure: Pregnancy Exposure (Bexsero): Trimester unknown Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 26-JUN-2026 The patient last menstrual period and due date were unknown. Nothing else had been reported.
Test Date: 20260624; Test Name: Pregnancy test; Result Unstructured Data: (Test Result:Positive,Unit:unknown,Normal Low:,Normal High:)